Valentina Greco takes on new position as President of the ISSCR – EurekAlert

image:

"My focus will be on people and scrutinizing processes so that they better support the diversity of needs of our members across identities including geographies and career stages," Dr. Greco said."In turn this will increase opportunities for professional growth of our members and augment our collective impact. As I commit to this vision, I equally commit to speak with openness about the struggles that we have and will experience in order to make this vision a reality.

Credit: Yale School of Medicine

The ISSCR is thrilled to announce Valentina Greco, Yale School of Medicine, Genetics Department andYale Stem Cell Center USA, as its President. Her term began at the ISSCR 2024 Annual Meeting held in Hamburg, Germany that concluded on Saturday, 13 July 2024.

I am honored to be taking on the role of ISSCR President for the coming year, Dr. Greco said. Building on Amander Clarks efforts, my focus will be on people and scrutinizing processes so that they better support the diversity of needs of our members across identities including geographies and career stages. In turn this will increase opportunities for professional growth of our members and augment our collective impact. As I commit to this vision, I equally commit to speak with openness about the struggles that we have and will experience in order to make this vision a reality, Dr. Greco added.

Valentina Greco was born in Palermo, Italy on 3 September 1972. She earned an undergraduate degree in Molecular Biology at the University of Palermo, Italy (1996) where she studied the role of tumor suppressors in cell cycle using in vitro system in the lab of Aldo Di Leonardo (1995-1998), her first academic research experience. She was accepted by Suzanne Eaton and the EMBL/MPI-CBG PhD program, Germany (1998-2002) and fell in love with microscopy and the power of developmental biology using fly wing imaginal disc as a model system to understand epithelial cell communication. Dr. Greco subsequentially completed a post-doc training in the Fuchs lab at the Rockefeller University (2003-2009) where she learned about the mammalian skin hair follicle as model system for stem cell driven regeneration. She was then hired as an Assistant Professor in the Genetics department at Yale School of Medicine by Richard Lifton and Haifan Lin (1 August 2009).

Dr. Greco is currently the Carolyn Walch Slayman Professor of Genetics as well as the Co-chair of Status of Women in Medicine (SWIM) at the Yale School of Medicine. She and members of her lab feel excited about visual driven research to study how cells behave in a living mouse. The team understands cell behaviors as an expression of the architectures and principles that govern the tissues thesecells inhabit, much like human behaviors are an expression of the systems and structuresin whichthey are embedded(e.g. a lab, anorganization). The Greco lab is passionate about identifying the mechanisms that govern communication and cooperation to sustain function over a lifetime.

Dr. Greco has served in numerous leadership roles in the scientific community including many within the ISSCR over the last decade. She also serves on numerous additional boards including President Elect for the Society of Investigative Dermatology (SID), SID Board member 2016-2020, Member of the National Arthritis and Musculoskeletal and Skin Diseases Advisory Council (NAMSAC (2022-2024)), Member of the Yale Ciencia Academy Advisory Committee, Member of the 2030STEM Leadership Team and Secretary of Board of Directors of the Life Science Editors Foundation (2020-2023).

Greco lab research has been recognized by numerous accolades awarded to both lab members and Dr. Greco. She in particular has received the 2014 Women in Cell Biology Junior Award (WICB) for Excellence in Research from the American Society of Cell Biology (ASCB), the 2014 ISSCR (International Society for Stem Cell Research) Outstanding Young Investigator Award, the 2015Robertson Stem Cell Investigator Award from the New York Stem Cell Foundation (NYSCF), the 2015 Mallinckrodt Scholar Award, the 2016 Early Career Award from the American Society of Cell Biology (ASCB), the 2016 HHMI Faculty Scholar Award, the 2017 Glenn Foundation Award, the 2017 Class of 61 Award by the Yale Cancer Center, the 2019 NIH DP1 Pioneer Award and the 2021 ISSCR Momentum Award. Dr. Greco finds it particularly meaningful to have received the 2018 Yale Mentoring Award in the Natural Sciences, the 2019 Yale Genetic Department Mentoring Award, the 2019 Yale Post-doc Mentoring Award.

The ISSCR is equally pleased to announce Hideyuki Okano, MD, PhD, Keio University, Japan is President-elect and will serve as president officially starting 1 July 2025. Lorenz Studer, MD, founding director of the Center for Stem Cell Biology and member of the Developmental Biology Program, Memorial Sloan Kettering Cancer Center, USA, is the new Vice President.

The following three members are newly elected to the ISSCR Board of Directors and beginning their three-year term: Jacqueline Barry, PhD, Cell and Gene Therapy Catapult, UK, Tenneille E. Ludwig, PhD, WiCell, USA, and Thomas A. Rando, MD, PhD, University of California, Los Angeles, USA.

The following members are starting their second, three-year term as a result of the 2024 election: Melissa Carpenter, PhD, Carpenter Consulting Corporation, USA, Malin Parmar, PhD, Lund University, Sweden, and Mitinori Saitou, MD, PhD, Kyoto University, Japan.

Learn more about the ISSCR Board of Directors.

About the International Society for Stem Cell Research With nearly 5,000 members from more than 80 countries, the International Society for Stem Cell Research is the preeminent global, cross-disciplinary, science-based organization dedicated to stem cell research and its translation to the clinic. The ISSCR mission is to promote excellence in stem cell science and applications to human health. Additional information about stem cell science is available at AboutStemCells.org, an initiative of the Society to inform the public about stem cell research and its potential to improve human health.

###

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Here is the original post:
Valentina Greco takes on new position as President of the ISSCR - EurekAlert

Cord Blood Hematopoietic Stem Cell Storage Market Revenue and Size Outlook | Cleveland Clinic., Cryo-Cell International, ViaCord, StemCyte Economica…

Press Release, July, 2024 (Orbis Research) The Cord Blood Hematopoietic Stem Cell Storage market is a dynamic and rapidly evolving sector that encompasses a wide range of products and services. The report aims to assist stakeholders in understanding the current state of the market and making informed decisions for their businesses.

Report Objective: The primary objective of this research report is to offer insights into the Cord Blood Hematopoietic Stem Cell Storage markets current trends, growth potential, and challenges. It seeks to provide a clear understanding of the markets type-wise performance, regional distribution, and the impact of the COVID-19 pandemic. Additionally, the report aims to identify key drivers influencing market growth, highlight the latest developments, and present a future outlook for the Cord Blood Hematopoietic Stem Cell Storage market.

Request a sample report @ https://www.orbisresearch.com/contacts/request-sample/7282693

Market Type Outlook: In this section, the report will analyze the different segments within the Cord Blood Hematopoietic Stem Cell Storage market based on types. It will provide a detailed assessment of each segments market size, growth rate, key players, and major trends. The report will also discuss the factors driving the demand for each type and the potential opportunities and challenges associated with them.

Regional Analysis: Under this section, the report will provide an in-depth analysis of the Cord Blood Hematopoietic Stem Cell Storage markets regional distribution. It will explore the markets performance in different geographical areas, including key growth regions, market saturation, and emerging markets. The regional analysis will also take into account factors such as economic conditions, regulatory landscape, and consumer preferences that influence market dynamics in each region.

Key Players

This section identifies and profiles the key players in the Cord Blood Hematopoietic Stem Cell Storage market. The assessment comprises an examination of their market dominance, range of products, financial achievements, and latest corporate approaches. Familiarity with the main participants aids in evaluating the competitive environment and fluctuations within the market.

Cord Blood Hematopoietic Stem Cell Storage market Segmentation by Type:

Autologous Storage, Public Repository

Cord Blood Hematopoietic Stem Cell Storage market Segmentation by Application:

Treat Blood Disorders, Rebuild Immune System, Research Use

Direct Purchase the report @ https://www.orbisresearch.com/contact/purchase-single-user/7282693

Strategic Outlook

This section outlines the strategic outlook for the Cord Blood Hematopoietic Stem Cell Storage market. It includes an analysis of the current market trends, opportunities, and challenges. Furthermore, the report offers suggestions to stakeholders on how to develop successful approaches that foster continuous growth and maintain competitiveness.

COVID-19 Impact: The report will investigate the impact of the COVID-19 pandemic on the Cord Blood Hematopoietic Stem Cell Storage market. It will discuss how the outbreak disrupted supply chains, altered consumer behavior, and affected demand patterns.

Limitations Outlook: This section will highlight the limitations of the research and the potential constraints that might have affected the accuracy and scope of the findings. It will provide transparency regarding data limitations, external factors, and other considerations that may influence the interpretation of the research results.

Key Players in the Cord Blood Hematopoietic Stem Cell Storage market:

Cleveland Clinic. Cryo-Cell International ViaCord StemCyte Smart Cells International LifeCell International Virgin Health Bank FamilyCord MiracleCord

Key Drivers of the Market: Here, the report will identify and analyse the key drivers propelling the growth of the Cord Blood Hematopoietic Stem Cell Storage market.

Latest Developments: The report covers the most recent developments and innovations in the Cord Blood Hematopoietic Stem Cell Storage market. Report also highlights product launches, mergers and acquisitions, strategic partnerships, and advancements in technologies that have shaped the markets landscape.

Regulatory Landscape and Policy Implications: This section will analyse the changing regulatory landscape in the Cord Blood Hematopoietic Stem Cell Storage market. Report also covers government and regulatory body response to the pandemic and its impact on market dynamics. The report gives insights into potential policy changes that could affect the market in the future and how businesses can prepare for them.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.orbisresearch.com/contacts/enquiry-before-buying/7282693

Future Outlook: The final section of the report will provide a future outlook for the Cord Blood Hematopoietic Stem Cell Storage market. It will discuss the projected market growth, potential challenges, and upcoming opportunities. The report will analyse the factors that are likely to influence the market in the coming years and offer insights for businesses to stay ahead in a competitive and evolving environment.

Conclusion: Cord Blood Hematopoietic Stem Cell Storage research report on the Cord Blood Hematopoietic Stem Cell Storage market has provided a comprehensive analysis of the current state and future prospects of the market. It has explored the type outlook, regional distribution, COVID-19 impact, key drivers, latest developments, and future outlook.

About Us

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have a vast database of reports from leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:

Hector Costello Senior Manager Client Engagements 4144N Central Expressway, Suite 600, Dallas, Texas 75204, U.S.A.

Read the original post:
Cord Blood Hematopoietic Stem Cell Storage Market Revenue and Size Outlook | Cleveland Clinic., Cryo-Cell International, ViaCord, StemCyte Economica...

Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology

PHILADELPHIA, July 22, 2024 (GLOBE NEWSWIRE) -- Vittoria Biotherapeutics,?a clinical-stage cell therapy company, announces a recent publication by investigators at the University of Pennsylvania in the peer-reviewed journal, Science Immunology. The publication details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the company’s proprietary Senza5TM platform. This technology, developed by the University of Pennsylvania and exclusively licensed to Vittoria, leverages the therapeutic potential of CD5 modulation to enhance the efficacy of CAR T-cell therapies and underscores its utility across multiple hematological and solid tumor animal models.

See more here:
Vittoria Biotherapeutics Announces Peer-Reviewed Publication in Science Immunology

Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

WESTLAKE VILLAGE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a virtual Key Opinion Leader (KOL) event featuring a leading dermatology and immune-mediated skin disease expert to discuss the unmet need and current treatment landscape for individuals with mild to moderate atopic dermatitis (AD). The event will highlight the differentiating features of and commercialization plans for ZORYVE® (roflumilast) cream 0.15%, which recently received FDA approval for the treatment of AD in adults and children down to age 6.

Read the original here:
Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOL

UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

SAN FRANCISCO, July 22, 2024 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced the appointment of Alicia Tozier, MBA, as chief strategy officer. In this new role, she will develop and implement the company’s corporate and product strategies.

See more here:
UNITY Biotechnology Announces Appointment of Alicia Tozier as Chief Strategy Officer

Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

CAMBRIDGE, Mass., July 22, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Karen Mahoney as Chief Human Resources Officer following the retirement of Heidi Hassen, who served as Vericel’s Head of Human Resources since September 2010.

More here:
Vericel Announces Appointment of Karen Mahoney as Chief Human Resources Officer

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

SAN JOSE, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it has entered into a securities purchase agreement with a single institutional investor for the purchase and sale of 2,800,000 shares of Rani Therapeutics’ Class A common stock (the “Common Stock”) and pre-funded warrants to purchase 446,753 shares of Common Stock, together with Series A common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock and Series B common warrants to purchase up to an aggregate of 3,246,753 shares of Common Stock, in a registered direct offering. Each share of Common Stock and pre-funded warrant is being sold together with one Series A common warrant to purchase one share of Common Stock and one Series B common warrant to purchase one share of Common Stock at a combined purchase price of $3.08. The Series A common warrants and Series B common warrants will each have an exercise price of $3.08 per share, will each be exercisable 6 months from the date of issuance, and, in the case of Series A common warrants, will expire 18 months from the date of issuance, and in the case of Series B warrants, will expire five and a half years from the date of issuance.

Read more:
Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200

NEW YORK and VIENNA, July 22, 2024 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK) (”HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Directors Dr. Malte Peters as Chief Executive Officer and Terry Coelho as Executive Vice President and Chief Financial Officer, effective July 22, 2024. They will both retain their positions on the Board of Directors (“Board”).

Go here to see the original:
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200